Short-course antimicrobial therapy of respiratory tract infections
- PMID: 14498754
- DOI: 10.2165/00003495-200363200-00002
Short-course antimicrobial therapy of respiratory tract infections
Abstract
Accumulating evidence suggests that short-course (</=5 days, </=3 days for azithromycin) antimicrobial therapy may be at least as effective as and, in some cases, may be more effective than traditional longer (10- to 14-day) therapies. In group A beta-haemolytic streptococcal tonsillopharyngitis, short-course therapy with 6 days of amoxicillin, 4-5 days of a variety of cephalosporins and 5 days of clarithromycin modified-release and telithromycin are all reasonable alternatives to traditional 10-day penicillin therapy. Short-course (i.e. 3-day) azithromycin therapy is not recommended because of suboptimal clinical and bacteriological results compared with penicillin therapy, unless the dosage is doubled from 10 to 20 mg/kg/day for all 3 days. In uncomplicated acute suppurative otitis media, single-dose intramuscular ceftriaxone or 3- to 5-day short-course oral antimicrobial therapy should be effective in the majority (>/=80%) of patients. However, more research is clearly needed in the subpopulations of children <2 years of age and in those with unresponsive/recurrent disease, since short-course therapy may not be successful in the majority of these patients. In sinusitis, most short-course therapy data have involved maxillary disease in adult patients. Regimens have included 3 days of azithromycin or cotrimoxazole (trimethoprim/sulfamethoxazole) or 5 days of cefpodoxime, telithromycin, gatifloxacin, gemifloxacin or amoxicillin/clavulanic acid. Preliminary results are encouraging but more study is clearly needed, especially in the paediatric population. In acute bacterial exacerbations of chronic bronchitis, short-course therapy with a variety of cephalosporins, second-generation fluoroquinolones and advanced generation macrolides/azalides/ketolides are all reasonable alternatives to traditional 7- to 14-day therapies. Cost containment in antimicrobial therapy should involve consideration of short-course therapy in the management of the most common types of respiratory tract infections.
Similar articles
-
Short-Course antimicrobial therapy for upper respiratory tract infections.Clin Ther. 2000 Jun;22(6):673-84. doi: 10.1016/S0149-2918(00)90003-1. Clin Ther. 2000. PMID: 10929916 Review.
-
Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.Pharmacoeconomics. 1996 Aug;10(2):164-78. doi: 10.2165/00019053-199610020-00008. Pharmacoeconomics. 1996. PMID: 10163419 Review.
-
Azithromycin. A review of its use in paediatric infectious diseases.Drugs. 1998 Aug;56(2):273-97. doi: 10.2165/00003495-199856020-00014. Drugs. 1998. PMID: 9711451 Review.
-
Cefuroxime axetil: an updated review of its use in the management of bacterial infections.Drugs. 2001;61(10):1455-500. doi: 10.2165/00003495-200161100-00008. Drugs. 2001. PMID: 11558834 Review.
-
Short-course therapy for acute sinusitis: how long is enough?Treat Respir Med. 2004;3(5):269-77. doi: 10.2165/00151829-200403050-00001. Treat Respir Med. 2004. PMID: 15606217 Review.
Cited by
-
Knowledge, perceptions and practices on antimicrobial resistance in humans and animals in Wakiso district, Uganda: A cross sectional study.PLOS Glob Public Health. 2023 Dec 13;3(12):e0002701. doi: 10.1371/journal.pgph.0002701. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 38091332 Free PMC article.
-
Treatment options for acute sinusitis in children.Curr Allergy Asthma Rep. 2004 Nov;4(6):471-7. doi: 10.1007/s11882-004-0014-4. Curr Allergy Asthma Rep. 2004. PMID: 15462714 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical